ORIC-114

Phase 1Small molecule

OORIC Pharmaceuticals

ORIC-114 is one of 84 small molecule programs targeting Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

NSCLCRecruiting

Solid TumorPreclinical

Recruiting

NSCLCPhase 1

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

DATROWAY

Daiichi Sankyo

Preclinical

1 2

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

3 3

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 4

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 5

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

Carboplatin AUC-5

Merck & Co.

Preclinical

1 9

Ifinatamab Deruxtecan

Daiichi Sankyo

Preclinical

1 10

IL-2

FFate Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

NSCLC

NCT06816992

Q3 2027

PreclinicalRecruiting

Solid Tumor

NCT05315700

Clinical

Trials by Indication[1]

NSCLC1 trial

ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC

Recruiting·OORIC Pharmaceuticals·Phase 1·NCT06816992·76 enrolled

Tics1 trial

Effect of Food on the Pharmacokinetics of ORIC-114

Completed·OORIC Pharmaceuticals·Phase 1·NCT06012721·32 enrolled

Solid Tumor1 trial

An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Recruiting·OORIC Pharmaceuticals·Preclinical·NCT05315700·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ORIC-114. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ORIC-114 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ORIC-114. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ORIC Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: OORIC Pharmaceuticals

ORIC-114

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Trials by Indication[1]

NSCLC1 trial

Tics1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News